Arena Pharmaceuticals Inc banner
A

Arena Pharmaceuticals Inc
F:RN3N

Watchlist Manager
Arena Pharmaceuticals Inc
F:RN3N
Watchlist
Price: 90.5 EUR 0.56% Market Closed
Market Cap: €5.6B

Multiples-Based Value

RN3N price has not been updated for more than 10 months. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the multiples-based value of RN3N.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RN3N Multiples-Based Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Multiples Across Competitors

RN3N Competitors Multiples
Arena Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Arena Pharmaceuticals Inc
F:RN3N
5.6B EUR 121 513.3 -10.6 -11.2 -11.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
369.2B USD 6 88.2 14.6 20.3
US
Amgen Inc
NASDAQ:AMGN
187.5B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
173.4B USD 5.9 20.4 12.7 15.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.4B USD 9.3 28.2 21.2 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.5B USD 5.6 17.9 13.3 15.2
AU
CSL Ltd
ASX:CSL
67B AUD 3.1 34 11.3 14.2
NL
argenx SE
XBRU:ARGX
39.6B EUR 11.3 36.2 39.3 40.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
A
Arena Pharmaceuticals Inc
F:RN3N
Average P/S: 3 074 049.4
121 513.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.3
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
NL
argenx SE
XBRU:ARGX
11.3
27%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
A
Arena Pharmaceuticals Inc
F:RN3N
Average P/E: 35.6
Negative Multiple: -10.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.2
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.4
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
13%
1.4
AU
CSL Ltd
ASX:CSL
34
10%
3.4
NL
argenx SE
XBRU:ARGX
36.2
32%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Arena Pharmaceuticals Inc
F:RN3N
Average EV/EBITDA: 18.1
Negative Multiple: -11.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.2
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
18%
0.7
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
NL
argenx SE
XBRU:ARGX
39.3
50%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Arena Pharmaceuticals Inc
F:RN3N
Average EV/EBIT: 20.3
Negative Multiple: -11.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.3
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.7
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
AU
CSL Ltd
ASX:CSL
14.2
10%
1.4
NL
argenx SE
XBRU:ARGX
40.1
51%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett